Seeking Alpha

Roche (RHHBY.PK -1.4%) has received premarket approval from the FDA for a new test to assess...

Roche (RHHBY.PK -1.4%) has received premarket approval from the FDA for a new test to assess patients for the cytomegalovirus. The fully automated process is the first FDA-approved laboratory test for use in quantifying the virus through DNA in human plasma specimens. Roche expects to begin shipping the new test kit in the U.S. in August.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|